56099
document
A comparative study of ofloxacin and amoxycillin/clavulanate in hospitalized patients with lower respiratory tract infections . We conducted an open randomized trial to compare the efficacy of parenteral and oral ofloxacin with that of amoxycillin/clavulanate . A total of 121 patients was studied ; 92 were clinically evaluable . Of these , 59 patients were treated with ofloxacin and 33 with the comparator drug . Patients were given the drugs intravenously for a minimum of three days followed by oral preparations for the next seven to ten days . Ofloxacin was usually administered as a 200 mg dose bd . In the ofloxacin treated group all patients showed clinical improvement . In the comparator group 94 % improved clinically ( either a complete or partial response ) , while 6 % were clinical failures . Of the bacteriologically evaluable patients 19 of 20 showed a satisfactory bacteriological response in the ofloxacin treated group , while in the comparator group the bacteriological response was judged satisfactory in 14 of 17 patients . A small proportion of patients ( 7 % ) treated with ofloxacin suffered mild adverse effects ( nausea , vomiting , headache , hypotension and rash ) . On the whole , ofloxacin was well tolerated by our patients . The two deaths that occurred were in the comparator group . We conclude that ofloxacin in both oral and parenteral forms is an effective and safe drug in the treatment of lower respiratory tract infections .
56100
Intervention_Pharmacological
ofloxacin
56101
Intervention_Pharmacological
amoxycillin/clavulanate
56102
Intervention_Pharmacological
ofloxacin
56103
Intervention_Pharmacological
amoxycillin/clavulanate
56104
Intervention_Pharmacological
ofloxacin
56105
Intervention_Pharmacological
Ofloxacin
56106
Intervention_Pharmacological
ofloxacin
56107
Intervention_Pharmacological
ofloxacin
56108
Intervention_Pharmacological
ofloxacin
56109
Outcome_Physical
lower respiratory tract infections .
56110
Outcome_Physical
clinical improvement .
56111
Outcome_Physical
satisfactory bacteriological response
56112
Outcome_Other
tolerated